Inflammatory Bowel Disease Plasma

About Inflammatory Bowel Disease Plasma

Inflammatory Bowel Disease Plasma for Immune-Mediated Inflammatory Disease Research

Inflammatory Bowel Disease Plasma is collected from IRB-consented donors clinically diagnosed with inflammatory bowel disease (IBD) and processed within one day of collection to preserve cytokines, proteins and metabolites. IBD — comprising Crohn’s disease and ulcerative colitis — is a chronic immune-mediated inflammatory disease of the gastrointestinal tract in which a dysregulated mucosal immune response to the gut microbiota, on a permissive genetic background and with a compromised epithelial barrier, drives relapsing inflammation. Plasma is acellular and is supplied for soluble-analyte work rather than cell-based assays.

Mucosal Immune Dysregulation and Why Plasma

• TNF and IL-23/IL-17 axis signalling is central to IBD pathogenesis and is the target of the anti-TNF and anti-IL-23/IL-12 biologics that dominate current therapy, making these cytokines the highest-value plasma analytes.
• Gut-homing and leukocyte trafficking: the alpha4beta7 integrin-MAdCAM-1 axis and sphingosine-1-phosphate receptor signalling direct lymphocytes to the intestine and are targeted by vedolizumab and S1P modulators; soluble trafficking-related markers are measurable in plasma.
• Epithelial barrier dysfunction generates circulating permeability and epithelial-damage markers, providing a non-invasive window on mucosal integrity.
• Systemic inflammatory burden: CRP and other acute-phase reactants, IL-6, and neutrophil-derived mediators track disease activity and support flare-prediction research.
• Therapeutic drug monitoring and immunogenicity: biologic drug levels and anti-drug antibodies are measured in circulation, and this cohort supports assay development for that purpose.
• Fibrosis and stricturing biology in Crohn’s disease can be studied through extracellular matrix turnover markers in the same aliquot.

Donor Stratification Available

• Disease subtype: Crohn’s disease versus ulcerative colitis, and IBD-unclassified where documented
• Disease activity at collection: active flare versus clinical remission
• Disease location and extent: ileal, colonic or ileocolonic Crohn’s; proctitis, left-sided or extensive colitis
• Behaviour: inflammatory, stricturing, or penetrating/fistulising Crohn’s disease
• Treatment status: anti-TNF biologic, anti-IL-23/IL-12 biologic, anti-integrin biologic, JAK inhibitor, S1P modulator, thiopurine, corticosteroid, 5-ASA, or treatment-naive
• Surgical history, including prior resection or ostomy
• Extraintestinal manifestations and comorbidities such as primary sclerosing cholangitis, spondyloarthritis, or hidradenitis suppurativa
• Matched healthy controls available

Product Features

• Research Use Only (RUO)
• Plasma collected from clinically confirmed inflammatory bowel disease donors
• Processed within one day of collection
• Anticoagulant selection available on request
• IRB-approved protocols and informed consent
• Custom aliquot volumes available upon request

De-identified Donor Data

• Verified inflammatory bowel disease diagnosis, with subtype where documented
• Demographic data: age, sex assigned at birth, race/ethnicity
• Donor-reported medications, allergies, and comorbidities
• Disease activity and treatment context reported per lot where captured
• Additional IBD-specific metadata available on request

Applications

• TNF-alpha, IL-6, IL-23 and IL-17 pathway cytokine profiling
• Disease activity and flare-prediction biomarker discovery and validation
• Gut permeability and epithelial damage marker measurement
• Acute-phase reactant and systemic inflammation characterisation
• Biologic drug level and anti-drug antibody assay development
• Extracellular matrix turnover and intestinal fibrosis marker research
• Plasma proteomic and metabolomic discovery, including microbiota-derived metabolites
• Crohn’s versus ulcerative colitis differential biomarker studies and therapeutic response research

Other Inflammatory Bowel Disease Specimen Types

• Inflammatory Bowel Disease Serum
• Inflammatory Bowel Disease Bulk Plasma
• Inflammatory Bowel Disease Whole Blood
• Inflammatory Bowel Disease PBMC
• Inflammatory Bowel Disease Leukopak
• Isolated subsets: CD4+ T cells, CD8+ T cells, CD3+ T cells, CD19+ B cells, CD56+ NK cells
• Subtype-specific cohorts: Ulcerative Colitis Plasma, Crohn’s Disease Bulk Plasma

Compliance and Quality Assurance

• IRB-approved and HIPAA-compliant protocols
• Electronic informed consent with 21 CFR Part 11 – compliant e-signatures
• Documentation support available for regulatory review

Ordering & Customization

Inflammatory bowel disease plasma is available in standard and custom volumes. For pricing, international orders, or documentation requirements, please email learnmore@sanguinebio.com to ensure compatibility with your country’s regulations. To compare collection formats or check wider availability, visit our human plasma page.